Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 主要终点
- SUVmax
研究概览
简要总结
To explore the value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in early diagnosis of treatment-related cardiotoxicity (TACT) of lymphoma using visual method and semi-quantitative method.
详细描述
First of all, the cardiac 18F-FDG uptake in patients with lymphoma will be observed by visual method: according to the uptake site, it will be divided into left ventricular uptake and biventricular uptake, and according to the degree of uptake, it will be divided into equal uptake (myocardial uptake is lower than cardiac blood pool uptake), moderate uptake (myocardial uptake is between cardiac blood pool uptake and liver uptake) and high uptake (myocardial uptake is higher than liver uptake). According to the uptake pattern, it can be divided into diffuse and segmental uptake.Then,using the region of interest method to mesure the value of myocardial uptake of 18F-FDG.The difference value of heart's SUVmax (Δ SUVmax- heart) and% Δ SUVmax- heart before and after chemotherapy or immunotherapy will be calculated. And SUVmax- heart / SUVmax- mediastinum ratio, SUVmax- heart / SUVmax- liver ratio and SUVmax- heart / SUVmax- background ratio (left gluteal muscle) after treatment. Taking the abnormality of ECG (early TACT) as the end point.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No previous history of heart disease.
- •normal echocardiography, ECG and laboratory tests (creatine kinase, myoglobin, troponin, brain natriuretic peptide) before treatment.
- •3.18F-FDG PET/CT examination before and after treatment
排除标准
- •1.receiving radiotherapy and chemotherapy at the same time. 2.previous chest radiotherapy.
- •with severe hepatic or renal dysfunction.
结局指标
主要结局
SUVmax
时间窗: 150 days
the standardized uptake value
次要结局
- SUVR(150 days)
研究者
Xuejuan Wang,MD
Principal INvestigaor
Peking University Cancer Hospital & Institute
